114 results about "Head and neck squamous-cell carcinoma" patented technology

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

The invention discloses the application of celastrol in the preparation of the medicine for treating cancer expressing CIP2A protein. The celastrol of the invention has the characteristics of having no obvious down regulation CIP2A protein with the cell line particularity, reducing the expressing of oncoprotein in lung cancer, liver cancer, breast cancer and gastric cancer with time and dose pendence, causing oncoprotein C-Myc steadied by CIP2A to generate corresponding retrogradation, displaying remarkable cytotoxic activity in the cell of lung cancer and liver cancer, and having effective function of anti-tumor proliferation in the transplant model of tumor of nude mice lung cancer. The celastrol has a wide application prospect in treating lung cancer, head and neck squamous cell carcinoma, carcinoma of colon, gastric cancer, liver cancer, breast cancer and other cancer expressing CIP2A oncoprotein.

Poly(ester-anhydrides) or polyesters formed from ricinoleic acid and natural fatty diacids and their method of preparation and its use for delivering bioactive agents including small drug molecules, peptides and proteins, DNA and DNA complexes with cationic lipids or polymers or nano and microparticles loaded with bioactive agents are disclosed herein. The drug delivery compositions are administered to a patient in a liquid form, increase in viscosity in vivo to form a drug depot or implant, and are able to release the incorporated bioactive agent for weeks. In the preferred embodiment, the drug delivery formulations are administered by injection. In one embodiment, the compositions are suitable for local or regional delivery of drugs to diseased sites, such as treating solid tumors and bone infections. In a preferred embodiment, the drug delivery compositions are suitable for site-specific chemotherapy for the treatment of solid tumors including: squamous cell carcinoma (SCC) of the head and neck, prostate cancer, and sarcomas for intratumoral injection or insertion.

The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.

The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention.

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.

The invention discloses an anti-tumor combination and the application thereof; the anti-tumor combination which includes effective dose of platinum-based chemotherapy and AKT inhibitor and / or p70S6K1 inhibitor has the function of inhibiting the drug resistance of the tumor to the platinum-based chemotherapy, improves the effects of anti-tumor drugs, and can be used for preparing drugs that can resist various tumors, such as lung cancer, ovarian cancer, prostate cancer, breast cancer, stomach cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer, osteosarcoma, etc.

The invention discloses a cycloalkane thiophthene derivative and pharmaceutically acceptable salts, metabolic products or prodrugs thereof. A compound can be used for treating diseases related with STAT3 (Signal Transducer and Activator of Transcription 3) activation, such as ovarian cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer, pancreatic cancer, lung cancer, brain cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, oral cancer, sarcoma, prostate cancer, head and neck squamous cell carcinoma, neuroglioma, melanoma, lymphoma, leukemia, and renal fibrosis, pulmonary fibrosis, rheumatoid arthritis, hair growth, arthritis, psoriasis, lupus erythematosus, inflammatory lung diseases and inflammatory bowel diseases. (The formula is shown in the description.).

The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.

The present disclosure relates to HLA-E as a tumor escape mechanism in head and neck cancer. The disclosure relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

Disclosed are protein biomarkers and their use in diagnosing head and neck squamous cell carcinoma (HNSCC) or to make a negative diagnosis in patients. Also disclosed are kits for the diagnosis of HNSCC that detect the protein biomarkers of the invention, as well as methods using a plurality of classifiers to make a probable diagnosis of HNSCC. In certain aspects of the invention, the methods include use of a decision tree analysis. Various computer readable media and their use according to the invention are also disclosed.

The invention relates to an application of lncRNA in preparation of products for predicting prognosis of head and neck squamous cell carcinoma, wherein lncRNA is a combination of RP11-180M15.7, RP11-197N18.2, AC021188.4, RP11-474D1.3 and RP11-347C18.5. In the specific embodiment, the product can be a chip or a kit or a detection device, and can also be a reagent for detecting the expression levelof RP11-180M15.7, RP11-197N18.2, AC021188.4, RP11-474D1.3 and RP11-347C18.5 in a sample to be tested. The reagent can be a probe for specially identifying RP11-180M15.7, RP11-197N18.2, AC021188.4, RP11-474D1.3 and RP11-347C18.5, and can also be a primer for specifically amplifying RP11-180M15.7, RP11-197N18.2, AC021188.4, RP11-474D1.3 and RP11-347C18.5. The application or product can reliably predict the prognosis of head and neck squamous cell carcinoma.

The invention provides methods of reducing the severity of a proliferative disorder. One method involves administering to an individual having the proliferative disorder an effective amount of paricalcitol, wherein the paricalcitol reduces cellular proliferation, with the proviso that the cancer is not prostate cancer or head and neck squamous cell carcinoma. Another method of reducing the severity of a proliferative disorder provided by the invention involves administering to an individual having the proliferative disorder an effective amount of paricalcitol and an anti-cancer agent, wherein the combination of paricalcitol and the anti-cancer agent reduces cell proliferation, with the proviso that the proliferative disorder is not prostate cancer or head and neck squamous cell carcinoma.

The invention discloses an immunity-related biomarker and an application of the biomarker to prognosis diagnosis of head and neck squamous cell carcinoma. The biomarker comprises four immune-related genes PVR, TNFRSF12A, IL-21R and SOCS1, and the biomarker and Path_N jointly form a head and neck squamous cell carcinoma prediction prognosis model. A group of new high-sensitivity and specific immunity-related molecular markers are developed for HNSCC prediction prognosis diagnosis to improve the outcome of a patient, which meets the current urgent demands. A model detection method is simple andeasy to operate, helps to better identify HNSCC patients, and can be used as a guidance basis for HNSCC immunotherapy decisions.

The invention relates to the construction of targeted NK cells used for tumor immunotherapy, and specifically relates to a preparation method for a membrane surface engineered NK cell, a pharmaceutical composition and an application. A targeting vector is adopted to introduce an azide group or DBCO on the surface of a NK cell, and polypeptide targeting PD-L1 can be coupled to the surface of the NKcell through copper-free click chemical reaction, so that a membrane surface engineered NK cell can be constructed. An application of the membrane surface engineered NK cell in treating PD-L1 positive tumor including head and neck squamous cell carcinoma, non-small cell lung cancer and triple negative breast cancer is also disclosed. Compared with the prior art, the preparation method has the following advantages: the targeting of the NK cell can be strengthened, so that potential hazards caused by viral vector transfection can be eliminated; the problems of CAR-T cell individualization and complex manufacturing processes can be solved; and the tumor infiltration capabilities and targeted killing activity of the NK cell can be enhanced, and immune escape mediated by a PD-1/PD-L1 pathway can be effectively blocked, so that the membrane surface engineered NK cell has potential clinical application prospets.

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

The present invention provides a method, referred to as CpG retrieval, to overcome incomplete bisulfite modification of DNA recovered from formalin-fixed tissue samples. The method involves boiling deparaffinized tissue samples in citrate buffer, followed by DNA extraction for promoter methylation analysis. In general, the extracted DNA is further modified by sodium bisulfite and then subjected to a method of promoter methylation analysis. The present invention also reports that hypermethylation of ataxia-telangiectasia-mutated gene promoter is correlated with decreased overall survival in patient with head and neck squamous cell carcinoma.